Timing of neuraxial procedures with anticoagulants

Surgical approach (if applicable)

• Not an operation: this topic relates to safe timing of neuraxial block and epidural catheter insertion/removal in anticoagulated patients.

Anaesthetic management (if applicable)

• Type of anaesthesia: neuraxial (spinal/epidural/CSE) often for lower limb/abdominal/obstetric surgery; may be combined with GA.
• Airway: if neuraxial alone → no airway device; if combined GA → SGA/ETT as indicated by surgery/aspiration risk.
• Duration: neuraxial placement typically minutes; catheter may remain 1–5 days depending on surgical/analgesic plan.
• How painful: depends on surgery; epidurals used for major abdominal/thoracic and some lower limb surgery; spinals common for hip/knee/CS.
• Key anaesthetic priority: minimise neuraxial haematoma risk by correct timing, atraumatic technique, and post-procedure neurological surveillance.

Core principles

• Neuraxial haematoma is rare but catastrophic; risk increases with anticoagulants, traumatic/multiple attempts, indwelling catheters, elderly/spinal pathology, and concomitant antiplatelets.
• Plan timing for: (1) needle/catheter insertion, (2) catheter removal, (3) restarting anticoagulant after insertion/removal.
• If block is traumatic (bloody tap/multiple attempts), consider delaying anticoagulant restart and increase neurological monitoring; document and discuss with surgical/haematology teams.
• Avoid combining multiple haemostasis-altering drugs (e.g., LMWH + clopidogrel) around neuraxial procedures unless specialist advice and compelling indication.
• Check renal function for renally cleared agents (LMWH, dabigatran, some DOACs) and adjust intervals accordingly.
• Ensure a clear post-neuraxial neuro-observation plan: motor power, sensory level, back pain, bladder/bowel function; rapid escalation pathway for suspected haematoma.

Aspirin and NSAIDs

• Aspirin (low dose) alone: neuraxial block and catheter removal can proceed without additional delay if no other coagulation issues.
• Non-selective NSAIDs alone: generally no additional timing restrictions for neuraxial procedures.
• Caution: risk rises when combined with anticoagulants (e.g., LMWH/DOAC) and with dual antiplatelet therapy.

P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) and other antiplatelets

• Clopidogrel: stop for 5–7 days before neuraxial insertion/removal (local policy often 7 days; 5 days may be acceptable with normal platelet function testing where available).
• Prasugrel: stop 7–10 days before neuraxial procedures (commonly 7 days minimum; many policies use 10 days).
• Ticagrelor: stop 5 days before neuraxial procedures.
• Restarting after neuraxial/catheter removal: usually can restart 6–24 h after (institution dependent); avoid immediate restart if traumatic or high-risk—seek cardiology advice if recent stent/ACS.
• GP IIb/IIIa inhibitors: very high risk; avoid neuraxial. If unavoidable, specialist guidance and appropriate drug-specific intervals (typically 8–48 h depending on agent) are required.

Unfractionated heparin (UFH)

• IV therapeutic UFH infusion: stop 4–6 h before neuraxial insertion/removal and confirm normal APTT (or anti-Xa per local practice).
• Restart IV UFH after neuraxial insertion/removal: typically ≥1 h after (many policies 1–2 h) if haemostasis secure and atraumatic.
• SC UFH prophylaxis (e.g., 5,000 units BD/TDS): perform neuraxial block 4–6 h after last dose (or per local policy); catheter removal similarly 4–6 h after last dose; next dose usually ≥1 h after removal.
• If UFH >4 days: check platelet count (HIT risk) before neuraxial procedures/catheter removal.

Low molecular weight heparin (LMWH: enoxaparin/dalteparin/tinzaparin)

• Prophylactic LMWH (once daily typical UK): wait ≥12 h from last dose before neuraxial insertion; same ≥12 h before catheter removal.
• Therapeutic LMWH (e.g., enoxaparin 1 mg/kg BD or 1.5 mg/kg OD): wait ≥24 h before neuraxial insertion/removal (longer if renal impairment).
• Restart LMWH after neuraxial insertion: typically ≥12 h (prophylactic) and ≥24 h (therapeutic) provided atraumatic and haemostasis secure.
• Restart LMWH after catheter removal: give next prophylactic dose ≥4 h after removal (many UK policies use 4 h); for therapeutic dosing, often delay longer and seek specialist advice.
• Avoid neuraxial techniques in patients receiving twice-daily LMWH prophylaxis regimens unless clear guidance and careful timing (higher peak/trough exposure).

Vitamin K antagonists (warfarin)

• Before neuraxial insertion: stop warfarin ~5 days and ensure INR is normal/acceptable for neuraxial (commonly INR ≤1.4; follow local threshold).
• Epidural catheter in situ with warfarin: requires daily INR monitoring; avoid catheter removal if INR above local threshold (commonly >1.4–1.5).
• Catheter removal: remove when INR acceptable (commonly ≤1.4); re-check INR if dose changes or clinical concern.
• Restart warfarin: can usually restart after neuraxial placement; ensure catheter removal occurs before INR rises (plan dosing and monitoring).
• Bridging with heparin/LMWH: apply the heparin/LMWH timing rules; bridging increases complexity and risk—document a clear plan.

Direct oral anticoagulants (DOACs)

• General: neuraxial procedures are high bleeding-risk; timing depends on drug, dose (prophylactic vs therapeutic), renal function, and last intake time.
• Rivaroxaban / Apixaban / Edoxaban: commonly wait at least 72 h before neuraxial insertion/removal for therapeutic dosing; consider longer if renal impairment, interacting drugs, or high bleeding risk.
• Dabigatran (thrombin inhibitor): more renal dependent; often requires ≥72–120 h depending on creatinine clearance (longer with reduced CrCl). Avoid neuraxial if renal impairment and timing uncertain.
• Restart after neuraxial insertion/catheter removal: typically ≥6 h (some policies 6–24 h) after catheter removal and only if haemostasis secure; avoid restarting with catheter in situ.
• If urgent neuraxial needed: generally avoid; consider alternative anaesthesia/analgesia. If life/limb-saving and reversal available, involve haematology and follow local pathways (e.g., idarucizumab for dabigatran; andexanet alfa for selected Xa inhibitors; PCC may be considered).

Fondaparinux

• Long half-life; higher neuraxial haematoma concern. Neuraxial techniques generally avoided unless strict timing and single-needle atraumatic technique.
• If used: many policies suggest wait ≥36–42 h before neuraxial insertion/removal and delay next dose ≥6–12 h after; follow local guidance.

Thrombolysis and fibrinolytics

• Absolute/near-absolute contraindication to neuraxial procedures due to very high bleeding risk.
• If thrombolysis given with neuraxial catheter in situ: urgent senior review; consider catheter management with haematology input; institute intensive neuro monitoring and low threshold for MRI/neurosurgical referral.

Peripheral nerve blocks vs neuraxial

• Deep plexus/deep peripheral blocks (e.g., lumbar plexus, paravertebral) carry similar bleeding consequences to neuraxial and often follow similar timing rules.
• Superficial compressible-site blocks may be safer but still require judgement, ultrasound, and consideration of drug timing and site compressibility.